CYTK
Live chart
What they do
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
For information only · Important disclosures
Grades vs sector
Momentum35th percentile in sectorC-
Percentile within its GICS sector across the S&P 1500.
Growth1st percentile in sectorF
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
Profitability23rd percentile in sectorD
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
Quality & financial health
Piotroski F-score 2/9 · last two fiscal years
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $88.0M | $-785.0M | $-534.8M |
| 2024 | $18.5M | $-589.5M | $-399.8M |
| 2023 | $7.5M | $-526.2M | $-415.7M |
| 2022 | $94.6M | $-389.0M | $-310.9M |
| 2021 | $70.4M | $-215.3M | $-191.4M |
| 2020 | $55.8M | $-127.3M | $-2.1M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -2.4%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -1.60 | -1.50 | +6.3% |
| 2026-05-05 | -1.65 | -1.67 | -1.3% |
| 2026-02-24 | -1.37 | -1.50 | -9.7% |
| 2025-11-05 | -1.57 | -1.54 | +1.6% |
| 2025-08-07 | -1.36 | -1.12 | +17.9% |
| 2025-05-06 | -1.36 | -1.36 | +0.2% |
| 2025-02-27 | -1.17 | -1.26 | -7.3% |
| 2024-11-06 | -1.24 | -1.36 | -9.3% |
Insider trades
$224.0K
$471.6K
$214.8K
$490.9K
$239.0K
$6.8M
$72.1K
$550.8K
$74.7K
$264.1K
$357.4K
$526.8K
Stats refreshed 2026-10-21 18:19:28 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026